Aptiva APS IgG and APS IgM complement the previously cleared Aptiva Connective Tissue Diseases (CTD) and Celiac Disease Reagents and expand the number of FDA-cleared analytes detected by Aptiva to 18. The Aptiva APS IgG and IgM, Celiac Disease, and CTD Reagents had previously obtained the CE mark.
Aptiva uses particle-based multi-analyte technology (PMAT), which processes multiple analytes simultaneously from a patient sample aliquot. By utilizing PMAT, Aptiva can deliver up to 960 results in an 8-hour shift for APS testing, allowing laboratories to handle high volumes efficiently with minimal hands-on intervention.
In addition to the APS, CTD and Celiac Disease assays, Aptiva will target additional Autoimmune disease states and has over 60 analytes in various development stages. These analytes are poised to improve the accuracy of Autoimmune disease diagnosis and support better patient management.
Congratulations to the entire Autoimmunity team for achieving this major milestone and advancing innovation in Autoimmune diagnostics!



